Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Inzinger, M; Wippel-Slupetzky, K; Weger, W; Richter, L; Mlynek, A; Fleischander, B; Scheurecker, C; Sandor, N; Mairhofer, D; Sator, PG; Moser-Oberthaler, S; Häring, N; Viznerova, P; Painsi, C; Tanew, A; Ponholzer, P; Tatarski, R; Brenner, W; Stingl, G; Salmhofer, W; Rappersberger, K; Klein, G; Saxinger, W; Auböck, J; Kölli, C; Trautinger, F; Steiner, A; Ratzinger, G; Strohal, R; Riedl, E; Lange-Asschenfeldt, B; Pehamberger, H; Volc-Platzer, B; Selhofer, S; Legat, FJ; Müllegger, R; Reider, N; Schmuth, M; Hintner, H; Hofer, A; Gruber-Wackernagel, A; Aberer, W; Quehenberger, F; Wolf, P.
Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
Acta Derm Venereol. 2016; 96(2):207-212
Doi: 10.2340/00015555-2214
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Inzinger Martin
- Wolf Peter
- Co-authors Med Uni Graz
- Aberer Werner
- Gruber-Wackernagel Alexandra
- Hofer Angelika
- Legat Franz
- Muellegger Robert
- Painsi Clemens
- Quehenberger Franz
- Salmhofer Wolfgang
- Weger Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.
- Find related publications in this database (using NLM MeSH Indexing)
- Activities of Daily Living -
- Adolescent -
- Adult -
- Aged -
- Aged, 80 and over -
- Austria -
- Biological Products - adverse effects
- Biological Products - therapeutic use
- Female -
- Humans -
- Immunosuppressive Agents - adverse effects
- Immunosuppressive Agents - therapeutic use
- Intention to Treat Analysis -
- Kaplan-Meier Estimate -
- Male -
- Middle Aged -
- Proportional Hazards Models -
- Psoriasis - diagnosis
- Psoriasis - drug therapy
- Psoriasis - immunology
- Registries -
- Retrospective Studies -
- Severity of Illness Index -
- Time Factors -
- Treatment Outcome -
- Tumor Necrosis Factor-alpha - antagonists & inhibitors
- Tumor Necrosis Factor-alpha - immunology
- Young Adult -
- Find related publications in this database (Keywords)
- psoriasis
- biologics
- drug survival
- effectiveness
- daily life conditions